 In 2002 the first results of two RCTs were published which had been conducted on unresectable HCC patients, designed to assess the impact producted by TACE on survival, and which demonstrated a statistically significant advantage in TACE-treated patients compared to controls: survival at 1, 2, and 3 years was 82, 63, and 29, respectively, in the TACE arm versus 63, 27, and 17, respectively, in the control group of the Llovet study, and survival at 1, 2, and 3 years was 57, 31, and 26, respectively, in the TACE arm versus 32, 11, and 3, respectively, the control group of the study conducted by Lo. Both studies confirmed that TACE was a safe procedure, with a low complication rate and that incidence of liver failure had not increased by a significant percentage in the TACE-treated group. A recent, systematic meta-analysis conducted on 14 trials published in literature, appropriately chosen to compare effects on survival exerted by TACE compared to the conservative treatment with tamoxifen confirmed the aforesaid findings. 